StaphOff Biotech

Hopkinton, United States Founded: 2011 • Age: 15 yrs
Medical products preventing resistant staphylococcal infections are developed.

About StaphOff Biotech

StaphOff Biotech is a company based in Hopkinton (United States) founded in 2011.. StaphOff Biotech has raised $25 thousand across 1 funding round. StaphOff Biotech offers products and services including CEN-101, CEN-103, and whISOBAX. StaphOff Biotech operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.

  • Headquarter Hopkinton, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Staphoff Biotech, Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $25 K (USD)

    in 1 rounds

  • Latest Funding Round
    $25 K (USD), Seed

    Oct 11, 2012

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of StaphOff Biotech

StaphOff Biotech offers a comprehensive portfolio of products and services, including CEN-101, CEN-103, and whISOBAX. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Inhibits bacterial communication and toxin production to combat infections.

Prevents biofilm formation and enhances antibiotic effectiveness against bacteria.

Targets Staphylococcal infections by stopping bacterial virulence factors.

Funding Insights of StaphOff Biotech

StaphOff Biotech has successfully raised a total of $25K through 1 strategic funding round. The most recent funding activity was a Seed round of $25 thousand completed in October 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $25,000
  • First Round

    (11 Oct 2012)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2012 Amount Seed - StaphOff Biotech Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by StaphOff Biotech

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - StaphOff Biotech

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Staphoff Biotech Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of StaphOff Biotech

StaphOff Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for drug-resistant bacterial infections are developed.
domain founded_year HQ Location
Pleuromutilin antibiotics are developed for MDR infections.
domain founded_year HQ Location
Developer of bacterial ribosome-targeting drugs for MDR infections
domain founded_year HQ Location
Developer of antibiotics for MDR infections
domain founded_year HQ Location
Therapies for multi-drug resistant infections are developed using bacteriophages.
domain founded_year HQ Location
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Staphoff Biotech

Frequently Asked Questions about StaphOff Biotech

When was StaphOff Biotech founded?

StaphOff Biotech was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is StaphOff Biotech located?

StaphOff Biotech is headquartered in Hopkinton, United States. It is registered at Hopkinton, Massachusetts, United States.

Is StaphOff Biotech a funded company?

StaphOff Biotech is a funded company, having raised a total of $25K across 1 funding round to date. The company's 1st funding round was a Seed of $25K, raised on Oct 11, 2012.

What does StaphOff Biotech do?

StaphOff Biotech was established in 2011 in Hopkinton, United States, within the pharmaceutical sector. Products are developed to prevent or treat resistant staphylococcal infections. CEN-101 is being advanced for applications as a topical drug, locally injectable formulation, intravenous administration, device coating solution, and sterile lock. Operations center on these antimicrobial solutions for medical use.

Who are the top competitors of StaphOff Biotech?

StaphOff Biotech's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.

What products or services does StaphOff Biotech offer?

StaphOff Biotech offers CEN-101, CEN-103, and whISOBAX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available